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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most deadly cancers in the world and its
incidence rate has consistently increased over the past 15 years in Canada. Although transarterial
embolization therapies are palliative options commonly used for the treatment of HCC, their efficacy is still
controversial. The objective of this guideline is to review the efficacy and safety of transarterial
embolization therapies for the treatment of HCC and to develop evidence-based recommendations.
Method: A review of the scientific literature published up to October 2013 was performed. A total of 38
studies were included.
Recommendations: Considering the evidence available to date, the CEPO recommends the following:
(i) transarterial chemoembolization therapy (TACE) be considered a standard of practice for the palliative
treatment of HCC in eligible patients; (ii) drug-eluting beads (DEB)-TACE be considered an alternative and
equivalent treatment to conventional TACE in terms of oncological efficacy (overall survival) and incidence
of severe toxicities; (iii) the decision to treat with TACE or DEB-TACE be discussed in tumour boards; (iv)
bland embolization (TAE) not be considered for the treatment of HCC; (v) radioembolization (TARE) not be
considered outside of a clinical trial setting; and (vi) sorafenib combined with TACE not be considered
outside of a clinical trial setting.
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Introduction
Worldwide, hepatocellular carcinoma (HCC) is the fifth most diag-
nosed cancer and the third cause of cancer mortality.1 Although the
incidence rate of HCC in Canada is lower compared with other
regions, an increase of 3.7% per year in men and of 2.4% per year
in women has been observed from 1998 to 2007.2 HCC usually
develops on a background of cirrhosis, which is most often caused
by hepatitis B or C, non-alcoholic steatohepatitis or alcohol abuse.
The choice of treatment is based on multiple factors and takes into
account not only the tumour stage but also the patient’s residual
hepatic function and general condition. In early disease stage, the
potentially curative treatments of HCC are surgical resection, liver
transplantation and local tissue ablation therapies. When these
options are not indicated, a palliative treatment is offered.
Transarterial embolization therapies are commonly used to act
locally in the intermediate disease stage and sorafenib is the indi-
cated systemic treatment in the advanced stage.3
Transarterial embolization therapies involve the transcatheter
delivery, through the hepatic artery, of solid particles into an
artery feeding the target tumour to block its blood supply. These
therapies include bland embolization (TAE), chemoembolization
(TACE), chemoembolization using drug-eluting beads (DEB-
TACE) and radioembolization (TARE). A combination treatment
with TACE and sorafenib has also been investigated recently with
the intention of delaying time to progression.4
The CEPO (Comité de l’évolution des pratiques en oncologie) is a
group of specialists in oncology reporting to the Institut national
d’excellence en santé et en services sociaux. Its role is to provide
physicians and other health professionals working in oncology
with evidence-based guidelines and clinical support tools to
optimize and standardize the clinical practice in the province
of Quebec (Canada). As of today, the efficacy of the early
transarterial embolization therapies (TAE and TACE) is still con-
troversial and the latest ones are still being investigated. Thus,
the CEPO reviewed the efficacy and safety of transarterial
embolization therapies for the treatment of HCC and made clini-
cal recommendations based on the best available evidence.
Methods
This article is an updated adaptation of an original clinical guide-
line available at http://www.msss.gouv.qc.ca/cancer. Initially, a
review of the scientific literature published up to February 2013
was performed in PubMed with the following keywords:
chemoembolization (MeSH), transarterial chemoemboliza-
tion, transcatheter chemoembolization, oily chemoembolization,
embolization, transarterial embolization, transcatheter emboliza-
tion, drug-eluting beads, radioembolization, transarterial
radioembolization, transcatheter radioembolization, microsphere
embolization, therasphere, sir sphere, selective internal radiation,
sorafenib, liver neoplasms (MeSH), liver cancer and HCC. Pro-
spective studies and meta-analyses were considered. Only meta-
analyses published from 2003 to February 2013 were included.
Comparative retrospective studies were also considered, providing
patients’ baseline characteristics were relatively balanced between
groups. Only studies comparing TACE, TAE or TARE to absence
of treatment, one to another, DEB-TACE to TACE and a combi-
nation of TACE and sorafenib to TACE were included. Studies
using transarterial embolization therapies for the treatment of
hepatic metastasis or as a bridge to transplantation were not con-
sidered. Studies using fine powder of cisplatin in suspension (not
available in Canada) were excluded. Economic studies were also
excluded. Abstracts of randomized controlled trials (RCTs) pre-
sented at relevant international conferences held in 2011 and 2012
were also reviewed. The literature review was subsequently
updated to cover the time period from February 2013 to October
2013. Only published articles or abstracts reporting efficacy results
from RCTs were included for that period.
The level of evidence of selected studies and the strength of
recommendations were evaluated using the American Society of
Clinical Oncology and the European Society for Medical Oncol-
ogy grading system.5 The original guideline was developed by a
CEPO sub-committee, reviewed by independent experts, and
finally adopted by the CEPO by consensus.
Results
The review of the literature included 38 articles. Transarterial
embolization therapies being indicated in palliative intent, overall
survival was regarded as the most important efficacy endpoint.
TACE
Seven prospective trials, including six RCTs, and five retrospective
trials evaluated the efficacy of TACE (Table 1).6–20 Two studies
investigated the effect of TACE on quality of life.7,21 All prospective
trials were of a small size. Results on overall survival were not
consistent across prospective studies: three studies demonstrated
increased overall survival with TACE,8,9,12 whereas the other four
showed no effect.6,7,10,11 All retrospective studies found that TACE
was associated with a survival benefit.13–17 Three meta-analyses
including RCTs investigating TACE and TAE,18,20 or TACE, TAE
and transarterial chemotherapy (TAC),19 compared the treat-
ments with absence of treatment or suboptimal treatment
(Table 2). In the two earlier meta-analyses, published in 2003 and
2007, TACE and TAE significantly reduced the mortality risk.18,19
In the most recent meta-analysis, published in 2011 by Oliveri
et al.20, TACE and TAE were associated with a 20% mortality risk
reduction, but this estimate did not reach statistical significance.
Overall, symptoms related to post-embolization syndrome
(fever, nausea and abdominal pain) were observed in up to 80%
of patients and were generally mild, transient and manageable.
The most common complications included liver failure, cholecys-
titis, gastro-intestinal bleeding, ascites and encephalopathy.
Treatment-related death rates varied between 0% and 6%. Quality
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Table 1 Summary of studies evaluating TACE
Study (median
follow-up)
Population Treatment n Tumour response
(A versus B)
Overall survival (A versus B)
Randomized controlled trial (Level of evidence II)
Doffoel et al. 20087
(A/B: 12.4/11 months)
Child–Pugh grade:
A: 70%, B: 30%
Okuda stage:
I: 72%, II: 28%
A) TACE + tamoxifen
B) Tamoxifen
Total: 123
A: 62
B: 61
NA Median: 13.8 versus 11 months
Cumulative rate:
– 1 year: 51% versus 46%
– 2 years: 25% versus 22%
P = 0.68
Llovet et al. 20028
(A/B/C: 21.2/21.7/
14.5 months)
Child–Pugh grade:
A: 71%, B: 29%
Okuda stage:
I: 65%, II: 35%
BCLC stage:
B: 80%, C: 20%
A) TACE
B) TAE
C) No treatment
Total: 112
A: 40
B: 37
C: 35
ORa ≥ 6 months, n = 102
– A versus C: 35% versus 0%;
P = 0.004
A versus C
Mean: 28.7 versus 17.9 months
Cumulative rate:
– 1 year: 82% versus 63%
– 2 years: 63% versus 27%
– 3 years: 29% versus 17%
P = 0.009
Risk of death:
HR: 0.47 (95% CI: 0.25–0.91);
P = 0.025
Lo et al. 20029
(NA)
Okuda stage:
I: 47%, II: 53%
A) TACE
B) No treatment
Total: 79
A: 40
B: 39
At 3 monthsb (n = 46)
– OR: 39% versus 6%;
P = 0.014
– CR: 0% versus 0%
Cumulative rate:
– 1 year: 57% versus 32%
– 2 years: 31% versus 11%
– 3 years: 26% versus 3%
P = 0.002
Risk of death:
RR: 0.50 (95% CI: 0.31–0.81);
P = 0.005
Pelletier et al. 199810
(698 days)
Child–Pugh grade:
A: 77%, B: 23%
Okuda stage:
I: 68%, II: 32%
A) TACE + tamoxifen
B) Tamoxifen
Total: 73
A: 37
B: 36
Within ≤250 daysb (n = 45)
– OR: 24% versus 5.5%;
P = 0.046
– CR: 0% versus 0%
Cumulative rate:
– 1 year: 51% versus 55%
– 2 years: 24% versus 26%
P = 0.77
Risk of death:
RR: 0.92 (95% CI: 0.55–1.56)
GETCH 19956
(NA)
Child–Pugh grade:
A: 100%
Okuda stage:
I: 90%, II: 10%
A) TACE
B) No treatment
Total: 96
A: 50
B: 46
At 2 monthsc (n = 81)
– OR: 53% versus 13%
– SD: 37% versus 37%
– PD: 9% versus 50%
P = 0.001
Cumulative rate:
– 8 months: 70% versus 50%
– 1 year: 62% versus 43.5%
– 2 years: 37.8% versus 26%
Risk of death (B versus A):
RR: 1.4 (95% CI: 0.9–2.2);
P = 0.13
Pelletier et al. 199011
(>1 year)
Okuda stage:
I: 26.2%, II: 52.4%, III: 21.4%
A) TACE
B) No treatment
Total: 42
A: 21
B: 21
A and Bd (P = NA)
– OR: 33% versus 0%
– CR: 19% versus 0%
Cumulative rate:
– 6 months: 33% versus 52%
– 1 year: 24% versus 31%
P = NS
Non-randomized prospective study (Level of evidence III)
Yuen et al. 200312
(NA)
Child–Pugh grade:
A: 79%, B: 21%
Okuda stage:
I: 67%, II: 33%
A) TACE
B) No treatment
Total: 96
A: 80
B: 16
A onlya (n = 75)
– OR: 28%
– CR: 2.7%
– SD: 44%
– PD: 28%
Median: 31.2 versus 14.1
months; P = 0.0126
Cumulative rate:
– 6 months: 98.3% versus
62.5%; P = 0.002
– 1 year: 86.3% versus 62.5%;
P = 0.023
– 2 years: 78.8% versus 50%;
P = 0.017
– 3 years: 57.5% versus 50%;
P = NS
– 4 years: 51.3% versus 43.8%;
P = NS
Retrospective study (Level of evidence IV)
Huang et al. 200615
(NA)
Child–Pugh grade:
A: 75%, B: 25%
CLIP stage:
2: 39%, 3–5: 61%
Tumours > 10 cm
A) TACE
B) No treatment
Total: 57
A: 31
B: 26
NA Median: 9.1 versus 2.1 months
Cumulative rate:
– 1 year: 41.9% versus 7.7%
– 2 years: 22.6% versus 7.7%
– 3 years: 12.9% versus 0%
– 4 years: 9.7% versus 0%
– 5 years: 6.5% versus 0%
P < 0.0001
Bronowicki et al.
199613
(NA)
Child–Pugh grade:
A: 100%
Okuda stage:
I: 100%
A) Resection
B) Transplantation
C) TACE
D) No treatment
Total: 122
A: 30
B: 17
C: 42
D: 33
NA Cumulative rate (C versus D):
– 3 years: 54% versus 11%
– 5 years: 47% versus 0%
A, B and C versus D:
P < 0.0001
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Table 1 Continued
Study (median
follow-up)
Population Treatment n Tumour response
(A versus B)
Overall survival (A versus B)
Stefanini et al. 199516
Matched historical control
(NA)
Child–Pugh grade:
A: 42.1%, B: 46.3%, C: 11.6%
Okuda stage:
I: 39%, II: 52.6%, III: 8.4%
A) TACE
B) TAC
C) No treatment
Total: 164
A: 69
B: 31
C: 64
NA Cumulative rate (A versus C):
– 6 months: 86% versus 27%
– 1 year: 73% versus 16%
– 2 years: 44% versus 8%
– 3 years: 36% versus 3%
– 4 years: 20% versus 0%
P < 0.001
Bronowicki et al. 199414
Matched case–control
(NA)
Child–Pugh grade:
A: 56.8%, B: 29.5%, C: 14.2%
Okuda stage:
I: 36.8%, II: 48%, III: 13.4%
A) TACE
B) No treatment
Total: 254
A: 127
B: 127
NA Cumulative rate:
– 1 year: 64% versus 18%
– 2 years: 38% versus 6%
– 3 years: 27% versus 5%
– 4 years: 27% versus NA
P < 0.0001
Vetter et al. 199117
Matched case–control
(NA)
Child–Pugh grade:
A: 48.3%, B: 41.7%, C: 10%
Okuda stage:
I: 26.6%, II: 46.6%, III: 26.6%
A) TACE
B) No treatment
Total: 60
A: 30
B: 30
NA Cumulative rate:
– 1 year: 59% versus 0%
– 2 years: 30% versus NA
P < 0.001
aTumour response based on WHO criteria.
bPartial tumour response defined as >50% reduction in tumour size.
cPartial tumour response defined as >25% reduction in the longest tumour diameter.
dTumour response as reduction in both tumour size and in AFP levels; partial tumour response defined as > 50% reduction of initial value.
BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; CLIP, Cancer of the Liver Italian Program; CR, complete response; HR, hazard ratio; n, number of patients; NA,
not available; NS, statistically non-significant; OR, objective response; PD, progressive disease; RR, relative risk; SD, stable disease; TAC, transarterial chemotherapy; TACE,
transarterial chemoembolization; TAE, embolization; WHO, World Health Organization.
Table 2 Summary of meta-analyses on TACE and TAE (level of evidence I)
Meta-analysis Treatment Number of
studies (n)
Heterogeneity Estimated risk of death
(95% CI)
Oliveri et al.
201120
TACE or TAE versus suboptimal or no treatment 8 (648) I2 = 31% HR: 0.81 (0.64–1.02);
P = 0.067
TACE versus suboptimal or no treatment 5 (489) I2 = 46% HR: 0.79 (0.58–1.06);
P = 0.11
TAE versus suboptimal or no treatment 3 (194) I2 = 0% HR: 0.94 (0.62–1.42);
P = 0.76
TACE or TAE versus no treatment 5 (410) I2 = 52% HR: 0.75 (0.53–1.07);
P = 0.12
Marelli et al.
200719
TACE, TAE or TAC versus suboptimal or no treatment 9 (632) χ2: P = 0.69 OR: 0.705 (0.499–0.994);
P = 0.0026
TACE or TAE or TAC versus no treatment 6 (460) NA OR: 0.674 (0.445–1.021)
TACE versus suboptimal or no treatment 5 (366) NA OR: 0.619 (0.377–1.016)
TAE versus suboptimal or no treatment 3 (215) NA OR: 0.746 (0.430–1.296)
TACE versus TAE 3 (447) χ2: P = 0.052 OR: 1.384 (0.94–2.04);
P = 0.1
Llovet and
Bruix 200318
TACE or TAE versus suboptimal or no treatment 6 (503) χ2: P = 0.14 At 2 years, OR: 0.53
(0.32–0.89); P = 0.017
TACE or TAE versus suboptimal or no treatment 7 (545) χ2: P = 0.14 At 1 year, OR: 0.64
(0.41–1.01); P = 0.051
TACE or TAE versus no treatment 4 (367) NA OR: 0.46 (0.23–0.89);
P = 0.022
TACE versus suboptimal or no treatment 4 (323) NA OR: 0.42 (0.20–0.88);
P = 0.021
TAE versus suboptimal or no treatment 3 (215) NA OR: 0.59 (0.29–1.20);
P = 0.14
CI, confidence interval; HR, hazard ratio; I2, heterogeneity test (<25%: low, 25–50%: moderate, > 50%: high); n, number of patients; NA, not available;
OR, odds ratio; TAC, transarterial chemotherapy; TACE, transarterial chemoembolization; TAE, embolization; χ2, heterogeneity test (P < 0.1: high).
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of life after TACE was not changed,7 or deteriorated less rapidly
compared with absence of treatment.21
TAE
Two RCTs compared the efficacy of TAE with absence of treat-
ment (level of evidence II).8,22 Llovet et al.8 chose a sequential
triangular design, and the TAE versus control comparison was
stopped prematurely. TAE did not significantly increase survival,
but a statistical trend was found [hazard ratio (HR): 0.57 (95%
confidence interval (CI): 0.31–1.04); P = 0.07]. Bruix et al.22
showed no change in overall survival with TAE (P = 0.72). The
three meta-analyses specifically evaluating the effect of TAE com-
pared with absence of treatment did not show any difference in
terms of overall survival between the two groups (Table 2).18–20
Two RCTs (levels of evidence I and II) and one retrospective
study (level of evidence IV) compared TAE with TACE and showed
no difference in overall survival.23–25 Although Chang et al.23
reported more emesis with TACE than TAE, the toxicity profile was
similar between the two treatments in the study from Kawai et al.24
TAE performed with Bead Block® has also been compared with
DEB-TACE in two small RCTs, one of them presented as an
abstract (level of evidence II and not evaluable).26,27 In the study
from Malagari et al.26, although the primary endpoint, median
time to progression, was significantly shorter for the Bead Block®
group (36.2 versus 42.4 weeks; P = 0.008), there was no difference
in overall survival between the groups at 12 months (86% versus
85.3%). In the abstract from Brown et al.26,27, the median overall
survival was similar in both groups (14 versus 16 months;
P = 0.7).27 Toxicity was similar with both treatments.
DEB-TACE
Three RCTs and four retrospective studies compared DEB-TACE
with conventional TACE (Table 3).28–34 Only one RCT provided
overall survival data;29 the primary efficacy endpoints were
tumour response or pharmacokinetic patterns in the other two
studies.28,30 No difference was observed in terms of overall survival
and tumour response between the treatments. A meta-analysis
published by Gao et al.35 in 2013 also showed no difference
between DEB-TACE and conventional TACE for different tumour
response parameters. However, a subgroup analysis of Lammer
et al.28 showed a better tumour response in favour of DEB-TACE
in patients presenting less favourable prognostic factors [Child–
Pugh B, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 1, prior radical treatment (recurrence) or bilobar
disease; 52.4% versus 34.7%; P = 0.038]. The peak and cumulative
blood levels of doxorubicin after treatment were significantly
lower with DEB-TACE than with conventional TACE.30 In the
three retrospective studies providing survival data, overall survival
was found to be longer with DEB-TACE than with conventional
TACE.31,32,34 However, objective tumour response data were less
consistent: two studies showed a better tumour response rate with
DEB-TACE31,32 and one study showed no difference between the
treatments.34
The two treatments caused toxicity at similar rates in terms of
post-embolization syndrome29,30,32,33,36 and an increase in biliru-
bin29,30,33,36 and albumin29 levels, but DEB-TACE was associated
with a reduced elevation of aspartate aminotransferase
(AST)28,30,32,36 and alanine aminotransferase (ALT)28–30,36 levels,
and a lower rate of constitutional symptoms,28,30 alopecia30 and
myelosuppression.30 However, the overall incidence of grade 3
and 4 toxicities was similar with the two treatments.36
TARE
Four retrospective studies compared the efficacy of TARE with
TACE (Table 4).37–40 Yttrium 90-coupled TheraSpheres®37,39,40 or
SIR Spheres®38 were used. All studies included patients with rela-
tively advanced disease: 12% to 28% with Barcelona Clinic Liver
Cancer (BCLC) stage C,39,40 6% with Okuda stage III38 and about
40% presenting with vascular invasion.37,38 Carr et al.37 showed
that patients treated with TARE had a significantly longer overall
survival than those treated with TACE, but when stratification
analyses were done to compare more similar patients, the effect
was not significant anymore. In the other three studies, overall
survival was similar with the two treatments.38–40 Tumour
response data were not consistent between studies. Carr et al.37
showed a better response rate with TARE, and the other two
studies showed no difference between the groups.38,39 In addition,
Salem et al.40 showed a significantly longer time to progression
with TARE than with TACE. A meta-analysis of retrospective
studies from Xie et al.41 demonstrated a survival benefit of TARE
over TACE [HR: 0.73 (95% CI: 0.60–0.88); P = 0.0009]. However,
another analysis including five studies specifically using yttrium
90-coupled beads showed no difference between TARE and TACE
in the 1-year overall survival rate [relative risk (RR): 1.04 (95% CI:
0.94–1.16); P = 0.45].
Kooby et al.38 observed fewer complications with TARE than
with TACE. Overall, TARE caused more fatigue, and TACE caused
more haematological toxicities and greater elevations of AST and
ALT levels. Other data, less consistent across studies, showed that
TARE was associated with less fever39 and abdominal pain.40
Combination of (DEB)-TACE and sorafenib
Two published RCTs,42,43 one RCT presented as an abstract44 and
two retrospective studies45,46 compared the combination (DEB)-
TACE and sorafenib to (DEB)-TACE and placebo (Table 5). The
primary endpoint of all three RCTs was time to progression and it
differed between studies.42–44 Sansonno et al.43 showed that
sorafenib delayed time to progression, Kudo et al.42 also observed
a delayed time to progression with sorafenib but this was not
confirmed by central review, and in Lencioni et al.44, time to pro-
gression was not significantly delayed with sorafenib. The addition
of sorafenib to (DEB)-TACE did not increase overall survival
compared with placebo.42,44 However, the two retrospective studies
comparing the combination of TACE and sorafenib to TACE
alone showed a longer overall survival in the sorafenib group.45,46
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Table 3 Summary of studies comparing DEB-TACE with conventional TACE
Study (median follow up) Population Treatment n Tumour response
(A versus B)
Overall survival
(A versus B)
Randomized controlled trial (Level of evidence II)
Sacco et al. 201129
(28.2 months)
Child–Pugh grade:
A: 81%, B: 19%
BCLC stage:
A: 66%, B: 34%
A) DEB-TACE
B) cTACE
Total: 67
A: 33
B: 34
At 1 montha
– OR: 100% versus 100%
– CR: 51.5% versus 70.6%
P = 0.1
Cumulative rate:
– 2 years: 86.8% versus
83.6%; P = 0.96
van Malenstein et al.
201130
(NA)
Child–Pugh grade:
A: 93%, B: 7%
BCLC stage:
A: 10%, B: 63%,
C: 27%
A) DEB-TACE
B) cTACE
Total: 30
A: 16
B: 14
At 6 weeksa
– SD: 77% versus 92%
– PD: 23% versus 8%
P = 0.54
NA
Lammer et al. 201028
PRECISION V
(NA)
Child–Pugh grade:
A: 83%, B: 17%
Okuda stage:
I: 91%, II: 9%
BCLC stage:
A: 26%, B: 74%
A) DEB-TACE
B) cTACE
Total: 212
A: 102
B: 110
At 6 monthsb
– OR: 51.6% versus
43.5%; P = 0.11c
– CR: 26.9% versus 22.2%
– SD: 11.8% versus 8.3%
– PD: 32.3% versus 40.7%
– DC: 63.4% versus 51.9%;
P = 0.11c
NA
Retrospective study (Level of evidence IV)
Song et al. 201232
(18 months)
Child–Pugh grade:
A: 92%, B: 8%
BCLC stage:
A: 44%, B: 56%
A) DEB-TACE
B) cTACE
Total: 129
A: 60
B: 69
At 3 months
– OR: 81.6% versus 49.4%
– CR: 55% versus 23.1%
– SD: 15% versus 30.4%
– PD: 3.4% versus 20.2%
P < 0.001
Mean: 32.2 versus 24.7
months
Cumulative rate:
– 6 months: 93%
versus 80%
– 12 months: 88%
versus 67%
– 18 months: 88%
versus 61%
P = 0.005
Song et al. 201133
Matched case-control
(NA)
Child–Pugh grade:
A: 85%, B: 15%
BCLC stage:
A: 32.5%, B: 40%,
C: 27.5%
A) DEB-TACE
B) cTACE
Total: 40
A: 20
B: 20
At 1 montha
– OR: 85% versus 30%;
P = 0.001
– CR: 35% versus 20%
– PD: 0% versus 0%
NA
Wiggermann et al. 201134
(NA)
Child–Pugh grade:
A: 100%
BCLC stage:
A: 12%, B: 76%,
C: 12%
A) DEB-TACE
B) cTACE
Total: 44
A: 22
B: 22
After average of 8 monthsb
– OR: 22.7% versus
22.7%; P = NS
– CR: 13.6% versus 0%
– SD: 68.2% versus 45.5%
– PD: 9.1% versus 31.8%
– DC: 90.9% versus 62.8%;
P = 0.066
Mean: 651 versus 414
days; P = 0.01
Cumulative rate:
– 1 year: 70% versus
55%
Dhanasekaran et al.
201031
(NA)
Child–Pugh grade:
A: 46.4%, B: 31%,
C: 22.6%
Okuda stage:
I: 33.3%, II: 49%,
III: 13.8%
CLIP stage:
0–3: 74.1%, 4–6:
25.9%
A) DEB-TACE
B) cTACE
Total: 71
A: 45
B: 26
NA Median: 403 versus
114 days; P = 0.016
Cumulative rate:
– 6 months: 71%
versus 50%
– 1 year: 58% versus
31%
– 2 years: 48% versus
12%
aTumour response based on RECIST criteria.
bTumour response based on EASL criteria.
cOne-sided P-value.
BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; CR, complete response; cTACE, conventional TACE; DC, disease
control; DEB, drug-eluting bead; n, number of patients; NA, not available; NS, statistically non-significant; OR, objective response; PD, progressive
disease; SD, stable disease; TACE, transarterial chemoembolization; RECIST, Response Evaluation Criteria in Solid Tumours; EASL, European
Association for the Study of the Liver.
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Sorafenib was generally not well tolerated and doses frequently
had to be reduced or the treatment stopped because of unaccep-
table toxicities. Common toxicities were hand/foot skin reactions,
haematological toxicities, hypertension, diarrhoea, alopecia,
elevation of serum lipase levels, rash and desquamation.42,43,45
Discussion
Transarterial embolization therapies are local palliative treatments
aiming to prolong survival in intermediate stage HCC patients.
Although some of these therapies have been used for many years
as standard, their efficacy is still being questioned.
TACE
Results from prospective studies comparing TACE with absence of
treatment were not consistent across studies,6–12 whereas all retro-
spective studies reported a survival benefit with TACE.13–15,17
However, the level of evidence of the latter studies is lower. From
a methodological point of view, all published RCTs were of low
power, and some aspects affected the study quality or the external
validity of most of them. Indeed, a number of flaws were observed:
patients with advanced disease stage were recruited (>20% of
Okuda III stage11 and at least 66% were symptomatic7); gelfoam
powder, recognized today as being unsafe, was used for TACE;11
groups were not balanced;6 about 15% of patients in the TACE
group received no or unsatisfactory treatments;7,10 and 7% of
patients in the control group received TACE.7 Previous studies
from Llovet et al.8 and Lo et al.9 had no major methodological
flaws.
Heterogeneity of RCTs’ results could not obviously be associ-
ated with any patient’s characteristic. However, it was noticed that
all three positive prospective studies8,9,12 were amongst the four
published after the year 2000.7–9,12 TACE procedure has improved
over the years, notably by the introduction of the use of
microcatheters at the end of the 1990s; these changes could have
improved the efficacy of the technique and explain the pattern of
results related to time.
Table 4 Summary of retrospective studies comparing TARE with TACE (level of evidence IV)
Study (median follow-up) Population Treatment n Tumour response
(A versus B)
Overall survival
(A versus B)
Moreno-Luna et al. 201239
Matched case-control
(≥52 months)
Child–Pugh grade:
A: 84%, B: 16%
BCLC stage (A versus B):
– A: 20% versus 42%
– B: 57% versus 24%
– C: 23% versus 35%
A) TARE
B) TACE
Total: 116
A: 61
B: 55
– OR: 51% versus 51%;
P = 1.00
– CR: 12% versus 4%;
P = 0.17
– SD: 39% versus 34%
– PD: 9% versus 15%
– DC: 89% versus 85%;
P = 0.56
Median: 15 versus 14.4
months; P = 0.47
Cumulative rate:
– 2 years: 30% versus 24%
– 3 years: 21% versus 16%
– 5 years: 9% versus 5%
Salem et al. 201140
(A/B: 22.7/32.6 months)
Child–Pugh grade:
A: 54.6%, B: 43.7%,
C: 1.6%
BCLC stage:
A: 36.7%, B: 51.4%,
C: 10.2%, D: 1.6%
A) TARE
B) TACE
Total: 245
A: 123
B: 122
– ORRa: 49% versus 36%;
P = 0.104
– Median TTR: 6.6 versus
10.3 months; P = 0.050
– ORRb: 72% versus 69%;
P = 0.748
– Median TTR: 1.2 versus
2.2 months; P = 0.016
Median TTP: 13.3 versus
8.4 months; P = 0.046
Median: 20.5 versus 17.4
months; P = 0.232
Risk of death:
HR: 1.06 (95% CI:
0.70–1.62); P = 0.780
Carr et al. 201037
(NA)
NA A) TARE
B) TACE
Total: 790
A: 99
B: 691
At 6 monthsa
– OR: 41% versus 60%
– CR: 3% versus 5%
– SD: 35% versus 29%
– PD : 23% versus 11%
– DC: 76% versus 89%
P = NA
Median: 11.5 versus 8.5
months; P < 0.0146
Kooby et al. 201038
(6 months)
Child–Pugh grade:
A: 49%, B: 51%
Okuda stage:
I: 39.4%, II: 56.3%, III:
5.6%
A) TARE
B) TACE
Total: 71
A: 27
B: 44
At 3 months
– OR: 11% versus 6%
– CR: 0% versus 2%
– SD: 41% versus 36%
– PD: 33% versus 36%
– DC: 52% versus 42%
P = 0.73
Median: 6 versus 6 months;
P = 0.74
Cumulative rate:
– 1 year: 16% versus 20%
Risk of death:
HR: 1.09 (95% CI:
0.61–1.92); P = 0.79
aTumour response based on WHO criteria.
bTumour response based on EASL criteria.
BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; CR, complete response; DC, disease control; HR, hazard ratio; n, number of patients;
NA, not available; OR, objective response; ORR, overall response rate; PD, progressive disease; SD, stable disease; TACE, transarterial
chemoembolization; TARE, transarterial radioembolization; TTP, time to progression; TTR, time to response; WHO, World Health Organization; EASL,
European Association for the Study of the Liver.
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Considering these heterogeneous results, meta-analyses were
of particular importance to conclude on the efficacy of TACE.
The Oliveri et al.20 meta-analysis has advantages over the two
earlier ones:18,19 it included all studies published on the subject to
date, and it used survival data of all time points (hazard ratio),
as opposed to survival data at a fixed time point (odds ratio).
Oliveri et al.20 showed that TACE was not significantly associated
with a survival benefit, but the P-value was close to the signifi-
cance threshold. The authors of three replies to this meta-
analysis criticized the studies selection.47–49 Forner et al.47 argued
that it was too permissive and explained why studies from
Akamatsu et al.50, Pelletier et al.11 and Doffoel et al.7 should not
have been included. In contrast, Ray et al.48 found the studies
selection too restrictive because only RCTs were considered,
ignoring a large body of evidence. Finally, Rose et al.49 argued
that the TACE procedure and patient selection criteria have
changed over the years, a point also acknowledged in the two
other replies, and that studies selection should have been based
on this criterion. Thus, they recalculated the estimates of mor-
tality risk by including only the three most recent studies,7–9 and
Table 5 Summary of studies evaluating combination TACE or DEB-TACE and sorafenib
Study (median
follow-up)
Population Treatment n Tumour response
(A versus B)
Overall survival
(A versus B)
Randomized controlled trial
Sansonno et al.
201243
Double blinded
Level of evidence II
(NA)
Inclusion criteria:
CR with TACE, HCV+,
Child–Pugh grade A,
BCLC stage B
A) TACE + sorafenib
B) TACE + placebo
Total: 80
A: 40
B: 40
Median TTP:
9.2 versus 4.9 months;
P < 0.001
Risk of progression:
HR: 2.5 (95% CI:
1.66–7.56)
NA
Kudo et al. 201142
Double blinded
Level of evidence I
(NA)
Inclusion criteria:
TACE response ≥25%,
tumor ≤3 cm,
Child–Pugh grade A
A) TACE + sorafenib
B) TACE + placebo
Total: 458
A: 229
B: 229
Central review
Median TTP: 5.4 versus
3.7 months
Risk of progression:
HR: 0.87 (95% CI:
0.70–1.09); P = 0.252
Cumulative PFS rate:
– 3 months: 65%
versus 58.7%
– 6 months: 45.7%
versus 33.5%
Median: 29.7 months
versus not reached
Cumulative rate:
– 1 year: 94.6% versus
94.1%
– 2 years: 72.1% versus
73.8%
Risk of death:
HR: 1.06 (95% CI:
0.69–1.64); P = 0.790
Retrospective study (Level of evidence IV)
Qu et al. 201245
Matched case-control
(NA)
Child–Pugh grade:
A: 76%, B: 24%
BCLC stage:
B: 37%, C: 63%
A) TACE + sorafenib
B) TACE alone
Total: 90
A: 45
B: 45
NA Median: 27 versus 17
months; P = 0.001
Tan et al. 201046
(A/B: 14/6 months)
Inclusion criteria:
multiple recurrence after
transplantation
Child-Pugh grade:
A: 55%, B: 45%
A) TACE + sorafenib
B) TACE alone
Total: 20
A: 10
B: 10
After 4 to 6 weeksa
– OR: 0% versus 10%
– CR: 0% versus 0%
– SD: 70% versus 30%
– PD: 30% versus 60%
– DC: 70% versus 40%
P = NS
Median
(post-recurrences):
14 versus 6 months;
P = 0.005
Risk of death – overall:
HR: 0.305 (95% CI:
0.104–0.890);
P = 0.03
Risk of death –
post-recurrence:
HR: 0.195 (95% CI:
0.057–0.669);
P = 0.009
Communication abstract (Level of evidence not evaluable)
Lencioni et al. 201244
(NA)
Child–Pugh grade: A
BCLC stage: B
A) DEB-TACE +
sorafenib
B) DEB-TACE + placebo
Total: 307
A: 154
B: 153
Risk of progression:
HR: 0.797 (95% CI:
0.588–1.080); P = 0.072
Median: not reached
Risk of death:
HR: 0.898 (95% CI:
0.606–1.330);
P = 0.295
aTumour response based on RECIST criteria.
BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; CR, complete response; DC, disease control; DEB, drug-eluting bead; HCV + , hepatitis
C virus seropositivity; HR, hazard ratio; n, number of patients; NA, not available; NS, statistically non-significant; OR, objective response; PD,
progressive disease; PFS, progression-free survival; SD, stable disease; TACE, transarterial chemoembolization; TTP, time to progression; RECIST,
Response Evaluation Criteria in Solid Tumours.
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found that TACE increased overall survival [HR: 0.79 (95% CI:
0.63–1.00)].
Overall data on TACE indicate that it is a relatively safe pro-
cedure. It is acknowledged that the incidence of complications and
deaths can greatly be reduced by a proper patient selection.51,52
Accordingly, the incidence of death is generally lower than 6% and
complication rates can be limited to about 10%.51
In summary, when considering the methodological quality of
studies and the improvement of the TACE procedure, the two
positive RCTs stand out as the ones that should be given more
weight.8,9 As for the Oliveri et al.20 meta-analysis, taken as it is, the
CEPO considers that it would be difficult not to recommend
TACE strictly on the basis of statistical considerations, as the
upper limit of the 95% CI barely exceeded the 1.00 significance
threshold value. This is besides the fact that, with today’s knowl-
edge, some authors consider that a few negative studies could have
been arguably left out,47–49 thus, the results would probably have
been positive.49 Although they are of lower level of evidence, the
non-randomized prospective study and the retrospective ones add
to the body of evidence showing the positive effect of TACE on
survival.12–14,16,17 For all these considerations, the CEPO recognizes
that TACE probably provides a survival benefit.
TAE
The evidence on the efficacy of TAE holds to two small RCTs,8,22
one of which was not properly completed.8 Both studies showed
that TAE does not significantly increase overall survival compared
with no treatment. The three TAE-specific meta-analyses also
showed no survival advantage with the treatment.18–20 In contrast,
other studies comparing TAE to TACE showed similar survival
results between the two treatments,23–25 suggesting that, just as
TACE, TAE also has an effect on survival. However, the methodo-
logical quality of these studies was poor and the evidence of an
actual effect only indirect. Similar results were reported with Bead
Block® TAE compared with DEB-TACE, although in one study,
the follow-up time was too short to evaluate survival26 and in the
second, too little details are available to fully appreciate the
results.27 Thus, the available data are not sufficient to definitively
conclude on the efficacy of TAE. Moreover, the CEPO feels that it
would be unethical to deny the potential effects of the local
chemotherapy that is part of the TACE procedure. With these
considerations in mind, TACE should be preferred to TAE.
However, in patients with contraindications to chemotherapy,
notably because of cardiac or renal co-morbidities, TAE could be
considered. But again, this is not based on solid evidence.
DEB-TACE
To date, only one RCT comparing the efficacy of DEB-TACE with
conventional TACE has published overall survival data. This
study, from Sacco et al.,29 recruited a small number of patients (n
= 67), but was otherwise of good quality. The PRECISION V
study, the largest one (n = 212), published data on tumour
response and safety so far.28,36 This study is not without flaws
however; besides the apparent imbalance between groups in terms
of Okuda stage distribution, about 10% of the patients dropped
out before the first treatment or the first imaging follow up,28 and
no embolizing agent was used at any time for nearly 28% of
patients of the TACE group.36 The other RCT, that of van
Malenstein et al.,30 compared the pharmacokinetics of DEB-TACE
with that of conventional TACE. In this small study (n = 30),
patients of the DEB-TACE group were older, and 43% of the
patients had received previous treatment.
Sacco et al.29 showed no difference between the two treatments
in terms of overall survival and all three RCTs reported no differ-
ence in tumour response.28–30 The absence of a difference in
tumour response was corroborated by the Gao et al.35 meta-
analysis. However, in patients with more advanced disease,
tumour response was better for DEB-TACE than with conven-
tional TACE.28 It is however worth mentioning that, with
transarterial embolization therapies, tumour response does not
necessarily translate into increased survival.6,10,11,22 The
pharmacokinetic data indicate that patients treated with DEB-
TACE are significantly less systemically exposed to doxorubicin
than those treated with TACE.30
Just like it was observed with TACE, data from retrospective
studies comparing DEB-TACE with conventional TACE are not
consistent with those of RCTs; indeed, longer overall survival was
observed with DEB-TACE.31,32,34 However, considering that the
follow-up of the Song et al.32 study was very short, and that the
disease stage of patients in the Dhanasekaran et al.31 study was
overall more advanced, their results must be interpreted
prudently.
Overall, DEB-TACE appears to be safer than conventional
TACE because the AST and ALT transient elevation is lower,
and the incidence of constitutional symptoms, alopecia and
myelosuppression are lower.28–30,32,33,36 However, alopecia and
myelosuppression are not very common toxicities, and AST
and ALT increased levels are not deleterious in themselves, so the
clinical significance of this apparent better tolerability is arguable.
Moreover, the overall incidence of grade 3 and 4 toxicities was very
similar with both treatments.36
In summary, the best level of evidence indicates that DEB-
TACE and conventional TACE are equivalent treatments in terms
of overall survival. However, the apparent better toxicity profile of
DEB-TACE does not seem clinically significant.
TARE
The four studies comparing TARE with TACE were retrospective
and of low methodological quality.37–40 Groups in all studies were
unbalanced. No difference in overall survival was found between
the treatments, except in the study by Carr et al.37 In this latter
study, however, when similar patients were compared with strati-
fication strategies, the survival effect disappeared. The meta-
analysis by Xie et al.41 confirmed these findings. Data on tumour
response were not consistently different between groups.37–39 Data
on toxicity showed that TARE is well tolerated.38–40 Salem et al.53
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published in 2013 a non-randomized prospective study (n = 56)
evaluating quality of life and showed that TARE may be associated
with a modestly better quality of life than TACE, at least when
certain subscales of the survey are considered separately. However,
the study had important limitations: the data collection was limited
to 4 weeks post-treatment and the groups were unbalanced regard-
ing tumour stages (TARE patients generally had a more advanced
disease).Thus,TARE is still in the investigation phase and RCTs will
be necessary to determine its place in the treatment of HCC.
Because of its microembolic effect,54 TARE could, in theory, be
the only local option to treat patients with portal vein thrombosis,
especially in the absence of collateral irrigation. The only com-
parative data on the subject come from Kooby et al.,38 in which
50% and 30% of the patients in the TARE and TACE groups
presented a vascular invasion. For the whole population, no sig-
nificant difference was observed between the groups in terms of
treatment-related death (7% versus 9%) and hepatic failure (7%
versus 14%). Moreover, in a recently published meta-analysis, Xue
et al.55 claimed that TACE can be relatively safe for the treatment
of HCC in the presence of a portal vein thrombosis. Thus, this
notion of TARE being safer than TACE for these patients needs to
be more formally demonstrated. In fact, the accumulating data on
the Asian experience with TACE for this indication challenges the
idea of considering portal vein thrombosis as an absolute con-
traindication for TACE, at least from a safety point of view (see
section on patient selection below).56–63 The efficacy of TACE in
this setting is still not clear though; this body of literature is of a
low evidence level and bears several methodological concerns,
making the data difficult to interpret. Consequently, the meta-
analysis of these data cannot be much more informative, besides
the important heterogeneity revealed with the analyses.55 Efficacy
needs to be confirmed in RCTs.
Combination of (DEB)-TACE and sorafenib
Results on time to progression were not consistent between
studies.42–44 Interestingly, the magnitude of the response needed in
these studies to go on with the administration of sorafenib was
more or less restrictive (complete response,43 ≥25% response42 or
no restriction44) and seemed to correlate with the ability of
sorafenib to delay time to progression.
The ultimate goal of delaying progression of the disease is to
increase survival. In this regard, RCTs showed that sorafenib had
no effect,42,44 whereas two small retrospective studies found that it
increased survival.45,46 As for safety, sorafenib was not well toler-
ated and caused severe toxicities in a large proportion of patients.
In summary, the best available evidence shows that the addition
of sorafenib to TACE adds considerable toxicity without provid-
ing survival benefits.
Patients selection for TACE (including DEB-TACE) and
treatment programme
TACE is a palliative treatment that should be offered to patients
ineligible for a potentially curative therapy. The decision to treat
with TACE must take into account the residual liver function, the
disease stage and the general condition of the patient. It is gener-
ally accepted that eligible patients to TACE are of intermediate
disease stage (BCLC B, ECOG performance status 0, large
multinodular tumours, Okuda stage I–II and Child–Pugh grade
A-B).64 However, in daily practice, with the actual poor knowledge
on the predictability of a survival benefit, safety and feasibility are
of particular importance to make a decision. The decision must be
discussed in a tumour board including preferably gastroenterolo-
gists (hepatologists), surgeons, medical oncologists, radiologists,
interventional radiologists and pathologists.3 The CEPO considers
the following criteria as absolute contraindications to TACE:
advanced cirrhosis (Child–Pugh ≥8, jaundice, encephalopathy,
refractory ascites and hepatorenal syndrome); bilobar tumour
replacing a large proportion of the liver; reversed portal flow;
contraindication to a transarterial procedure (e.g. non
embolizable intra-hepatic arteriovenous shunt, absence of
vascularization at imaging); and extra-hepatic metastases. The
relative contraindications to TACE are: tumour size ≥10 cm (con-
sider hepatic residual function); portal vein thrombosis;
co-morbidity involving the dysfunction of an organ (e.g. cardio-
vascular disease and active pulmonary disease); renal failure;
biliary obstruction; and aerobilia. In the presence of a portal vein
thrombosis, the CEPO considers that TACE can be safe only in
highly selected patients, when the presence of factors reducing the
risk of liver failure are present [e.g. thrombosis in the right or left
branch, good hepatic reserve (Child Pugh < 8), evidence of portal
collateral vascularization and feasibility of superselective
embolization (segmental or further)].
Re-treatment with TACE can result in an increased tumour
response.52,65 However, too aggressive a repetition programme can
lead to complications, including hepatic decompensation.52 The
Society of Interventional Radiology,51 as well as Lencioni et al.,66
suggested that TACE should not be systematically repeated, but
only in the presence of a residual viable tumour or intra-hepatic
progression. When a complete response is achieved, the tumour
should be followed by imaging every 2 to 3 months.
If the tumor is not responding after two consecutive TACE ses-
sions, the treatment should be stopped.66 The Assessment of
Re-Treatment with TACE (ART) prognostic system is a newly
available tool that can be considered for a re-treatment decision
after the first TACE.67 Although the modified RECIST response
system appears to be the one correlating best with overall sur-
vival,68,69 the EASL response system has to be used when using the
ART prognostic system.67 With these considerations in mind, the
CEPO suggests a TACE treatment programme algorithm in Fig. 1.
Conclusion and recommendations
The CEPO acknowledges the therapeutic value of TACE for the
palliative treatment of HCC for selected patients. DEB-TACE pro-
vides a survival benefit similar to that of TACE and is considered
an equivalent alternative. In patients with less favourable criteria,
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DEB-TACE seems to cause a better tumour response than con-
ventional TACE. Moreover, the incidence of some toxicities is
lower with DEB-TACE, although that of grade 3 and 4 toxicities is
overall similar. TACE or DEB-TACE should be preferred to TAE.
TARE is still in the experimental phase and should not be used
outside of clinical trials. Finally, the administration of sorafenib
together with TACE does not add a survival advantage and should
not be used outside of clinical trials.
Considering the evidence available to date, the CEPO recom-
mends the following:
Eligible patient 
TACE 
Partial response 
Stabilization 
Progression 
Partial response or 
viable tumour
No response 
2nd consecutive 
occurence Complete response 
TACE 
Stop TACE 
4-6 weeks
3 months
3 months 
No response 
1st occurence 
Complete response 
CT scan/MRI 
(mRECIST and EASL) 
CT scan/MRI 
(mRECIST) 
To consider To consider
Re-treatment? 
Consider: tolerance 1st TACE 
and ART1 score 
Figure 1 Suggested (TACE) programme algorithm. Algorithm inspired from Raoul et al.52 See details in the ‘Patients selection for TACE
[including drug-eluting beads (DEB)-TACE] and treatment programme’ section.1 Assessment of Re-Treatment with TACE (ART) overall
survival prognostic system.67 This system is based on the EASL response criteria.70 CT, computer-assisted tomography; EASL, European
Association for the Study of the Liver; mRECIST, modified Response Evaluation Criteria in Solid Tumours;71 MRI, magnetic resonance
imaging; TACE, transarterial chemoembolization
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1 TACE be considered a standard of practice for the pallia-
tive treatment of HCC in eligible patients (Grade C
recommendation);
2 DEB-TACE be considered an alternative and equivalent treat-
ment to conventional TACE in terms of oncological efficacy
(overall survival) and incidence of severe toxicities (Grade B
recommendation);
3 the decision to treat with TACE or DEB-TACE be discussed in
tumour boards, preferably including gastroenterologists
(hepatologists), surgeons, medical oncologists, radiologists,
interventional radiologists and pathologists (Grade D
recommendation);
4 TAE not be considered for the treatment of HCC (Grade C
recommendation), except in patients with contraindications
to the chemotherapy used in the TACE procedure (e.g. in
patients with cardiac or renal co-morbidities, grade D
recommendation);
5 TARE not be considered outside of a clinical trial setting (Grade
B recommendation); and
6 sorafenib combined with TACE not be considered outside of a
clinical trial setting (Grade B recommendation).
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